Shinhan Investment & Securities maintained its investment opinion 'buy' and target stock price of 135,000 won for Orion.

COMPANY / Kim Minyoung / 2024-07-17 07:46:07

(Photo= Yonhap news)

 

[Alpha Biz= Reporter Kim Minyoung] Shinhan Investment Corp. anticipates that Orion will achieve its expected performance for the second quarter of this year. The firm maintains a 'Buy' rating and a target price of 135,000 KRW.

Shinhan Investment Corp. stated, "For the second quarter of this year, we expect sales to increase by 0.4% year-on-year to 721 billion KRW, and operating profit to rise by 6.6% to 124.8 billion KRW." They explained, "Sales in China are projected to decline by 1% in yuan terms, and some channels have transitioned to indirect sales, resulting in a sales gap."

However, the operating profit margin is expected to increase by 0.9 percentage points (p) year-on-year due to lower raw material costs and reduced sales discounts. In the second half, Orion plans to gradually increase sales by filling channel gaps and expanding the distribution of new products.

Orion has been left out of the K-food rally cycle due to its lower sales growth rate and investments in the biotech sector unrelated to its core business. To address this, it needs to strengthen its product and channel competitiveness.

Shinhan Investment Corp. commented, "The current valuation is excessively undervalued at a 12-month forward price-to-earnings ratio (PER) of 8.8 times," and explained, "The target price was calculated with a 20% discount to the global industry average."

 

 

Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)

어플

주요기사

Kolmar Korea Certified as Year’s First ‘Reshoring’ Company; To Invest 100 Billion KRW in Smart Factory Expansion
Court Dismisses Additional Lawsuits by Shareholders Over "Invossa" Controversy, Ruling in Favor of Kolon
Nvidia Delays China H200 Chip Exports Amid Ongoing Talks With U.S. Government
Naver Issues Formal Apology Over Exposure of Celebrities’ and Politicians’ Past "Ji-sik-iN" Posts
CJ Logistics Designated as Unfaithful Disclosure Corporation Over Delayed Notice of $2.7B Libyan Counterclaim
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

SNS